Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Meropenem Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
14 September 2023
This article summarized the latest R&D progress of Meropenem, the Mechanism of Action for Meropenem, and the drug target R&D trends for Meropenem.
Latest Hotspot
3 min read
Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13
14 September 2023
Carrick Therapeutics made an announcement that their IND application for CT7439 has been given the green light by U.S FDA.
Drug Insights
4 min read
Unleashing the Power of Meprobamate: A Comprehensive Review on R&D Breakthroughs
14 September 2023
This article summarized the latest R&D progress of Meprobamate, the Mechanism of Action for Meprobamate, and the drug target R&D trends for Meprobamate.
Advanced Tech.
9 min read
Wang Shaomeng's research group reports AR receptor PROTAC drug ARD-1676, with a bioavailability as high as 99%
14 September 2023
The research group of Wang Shaomeng recently published a paper in JMC, reporting the discovery of ARD-1676 and characterizing its preclinical properties.
Drug Insights
4 min read
A Comprehensive Review of Lubiprostone's R&D Innovations and Drug Target Mechanism
14 September 2023
This article summarized the latest R&D progress of Lubiprostone, the Mechanism of Action for Lubiprostone, and the drug target R&D trends for Lubiprostone.
Latest Hotspot
3 min read
Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
14 September 2023
Opus Genetics has administrated to the first patient in its first-in-human Phase 1/2 clinical trial for OPGx-LCA5.
Drug Insights
4 min read
Pharmaceutical Insights: Linaclotide's R&D Progress and its Mechanism of Action on Drug Target
14 September 2023
This article summarized the latest R&D progress of Linaclotide, the Mechanism of Action for Linaclotide, and the drug target R&D trends for Linaclotide.
Drug Insights
4 min read
Exploring Leflunomide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
14 September 2023
This article summarized the latest R&D progress of Leflunomide, the Mechanism of Action for Leflunomide, and the drug target R&D trends for Leflunomide.
Latest Hotspot
3 min read
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
14 September 2023
Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.
Drug Insights
4 min read
Decoding Lacosamide: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
14 September 2023
This article summarized the latest R&D progress of Lacosamide, the Mechanism of Action for Lacosamide, and the drug target R&D trends for Lacosamide.
Drug Insights
4 min read
Deep Scientific Insights on Isosorbide Dinitrate's R&D Progress
14 September 2023
This article summarized the latest R&D progress of Isosorbide Dinitrate, the Mechanism of Action for Isosorbide Dinitrate, and the drug target R&D trends for Isosorbide Dinitrate.
Latest Hotspot
4 min read
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
14 September 2023
Janssen Pharmaceuticals filed a Marketing Authorisation Application with EMA to get approval for Erdafitinib. The drug is for adult patients with advanced or metastatic urothelial carcinoma, showing progression after a PD-1/PD-L1 inhibitor therapy, with susceptible FGFR3 mutations.